Primary empiric frame
Standard pneumonia pathway: respiratory syndrome classification, severity, MRSA/Pseudomonas risk, and culture quality.
Pharmacist.Guide / antimicrobial decision engine
Patient data in. Treatment plan out.
Built like a RapidPEP-style clinical engine for infectious disease: structured variables, prior cultures, resistance memory, and a visible reasoning trail.02
Treatment Plan
PneumoniaStewardship review recommended
Initial coverage direction
Use an inpatient pneumonia backbone. Add MRSA or antipseudomonal coverage only when severity, prior isolates, local risk, or validated screening supports it.
MRSA memory
Prior MRSA signal detected. Decide whether it matches the current syndrome before adding or continuing MRSA-active coverage.
Diagnostics
- Assess CAP/HAP/VAP context
- Obtain quality respiratory culture when severe or resistant risk exists
- Review MRSA nares and prior respiratory isolates
Safety / Dosing
- Renal function entered: CrCl 54 mL/min. Dose-adjust where required.
- Weight entered: 82 kg. Check weight-based dosing when applicable.
- No beta-lactam allergy entered.
Warnings
- Source control is not confirmed. Regimen selection alone is insufficient.
De-escalation instruction
Confirm oxygen trajectory, imaging pattern, aspiration context, and need for ICU-level coverage. Short course once clinically stable, adjusted by pathogen, complications, and response.
03
Past Culture + Resistance Memory
E. coli
Urine
ESBL; resistant ceftriaxone and ciprofloxacin; susceptible meropenem and nitrofurantoin
ESBL
MRSA screen
Nares PCR / current-source match
MRSA detected
MRSA